Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.96 Insider Own3.56% Shs Outstand58.56M Perf Week-0.78%
Market Cap111.85M Forward P/E- EPS next Y-0.85 Insider Trans1.38% Shs Float56.48M Perf Month24.03%
Income-43.15M PEG- EPS next Q-0.24 Inst Own69.91% Short Float0.18% Perf Quarter67.54%
Sales10.74M P/S10.41 EPS this Y41.62% Inst Trans0.71% Short Ratio0.20 Perf Half Y4.95%
Book/sh1.68 P/B1.14 EPS next Y8.57% ROA-39.03% Short Interest0.10M Perf Year-12.79%
Cash/sh1.74 P/C1.10 EPS next 5Y13.00% ROE-49.15% 52W Range1.08 - 2.70 Perf YTD35.46%
Dividend Est.- P/FCF- EPS past 5Y42.86% ROI-38.40% 52W High-29.26% Beta1.25
Dividend TTM- Quick Ratio8.33 Sales past 5Y569.37% Gross Margin71.78% 52W Low76.84% ATR (14)0.13
Dividend Ex-Date- Current Ratio8.33 EPS Y/Y TTM41.61% Oper. Margin-436.82% RSI (14)59.79 Volatility10.10% 7.85%
Employees70 Debt/Eq0.15 Sales Y/Y TTM- Profit Margin-401.81% Recom1.00 Target Price23.20
Option/ShortYes / Yes LT Debt/Eq0.14 EPS Q/Q57.61% Payout- Rel Volume1.00 Prev Close1.89
Sales Surprise-76.47% EPS Surprise11.50% Sales Q/Q- EarningsNov 09 AMC Avg Volume496.12K Price1.91
SMA206.85% SMA5021.43% SMA20010.71% Trades Volume495,717 Change1.06%
Date Action Analyst Rating Change Price Target Change
Jul-05-23Downgrade Oppenheimer Outperform → Perform
Oct-12-21Initiated RBC Capital Mkts Outperform $22
Sep-21-21Initiated Piper Sandler Overweight $19
May-10-21Initiated Laidlaw Buy $18
Aug-17-20Upgrade H.C. Wainwright Neutral → Buy $13
Mar-04-20Initiated ROTH Capital Buy $15
Mar-02-20Initiated Oppenheimer Outperform $8
Feb-14-18Downgrade JP Morgan Neutral → Underweight
Sep-07-17Initiated Piper Jaffray Overweight $7
Dec-13-16Downgrade JP Morgan Overweight → Neutral
Feb-21-24 08:00AM
Jan-29-24 08:00AM
Jan-18-24 08:00AM
Nov-13-23 08:00AM
Nov-09-23 04:07PM
04:00PM Loading…
Nov-01-23 08:00AM
Oct-31-23 08:00AM
Sep-11-23 08:00AM
Aug-30-23 09:35AM
Aug-24-23 08:00AM
Aug-09-23 05:30PM
Jul-20-23 07:30AM
07:00AM Loading…
Jun-28-23 07:00AM
Jun-22-23 08:00AM
Jun-20-23 08:00AM
Jun-09-23 04:00PM
Jun-06-23 08:00AM
May-25-23 08:00AM
May-22-23 08:00AM
May-13-23 08:06AM
May-11-23 04:00PM
May-10-23 06:11AM
May-09-23 05:15PM
May-07-23 04:00AM
02:24PM Loading…
May-05-23 02:24PM
Apr-17-23 08:00AM
Mar-30-23 08:00AM
Mar-28-23 10:45AM
Mar-23-23 07:10AM
Mar-21-23 08:00AM
Mar-20-23 08:00AM
Mar-09-23 05:15PM
Mar-08-23 08:00AM
Mar-02-23 08:00AM
Mar-01-23 08:00AM
Feb-17-23 12:00PM
Feb-10-23 05:21AM
Feb-09-23 08:00AM
Feb-08-23 04:11PM
Feb-06-23 08:00AM
Jan-31-23 08:00AM
Jan-19-23 08:00AM
Jan-18-23 08:00AM
Dec-29-22 06:59PM
Dec-15-22 08:00AM
Nov-18-22 04:00PM
Nov-10-22 05:15PM
Nov-09-22 08:00AM
Nov-03-22 08:02AM
Oct-25-22 08:00AM
Oct-11-22 08:00AM
Oct-04-22 08:00AM
Sep-29-22 08:00AM
Sep-27-22 08:00AM
Sep-16-22 08:35AM
Sep-13-22 08:00AM
Sep-12-22 08:35AM
Sep-09-22 11:52AM
Sep-06-22 08:00AM
Sep-01-22 08:00AM
Aug-15-22 04:00PM
Aug-12-22 04:05PM
Aug-11-22 08:03AM
Aug-04-22 08:00AM
Jun-24-22 02:22PM
Jun-14-22 08:00AM
Jun-13-22 08:00AM
Jun-01-22 08:00AM
May-17-22 08:00AM
May-16-22 08:00AM
May-13-22 04:00PM
May-10-22 02:00PM
May-09-22 05:15PM
May-02-22 08:00AM
Apr-14-22 12:14PM
Apr-13-22 08:00AM
Apr-11-22 08:00AM
Apr-06-22 09:55AM
Apr-02-22 03:25PM
Apr-01-22 11:45AM
Mar-31-22 01:05PM
Mar-25-22 04:00PM
Mar-22-22 08:48PM
Mar-21-22 10:00AM
Mar-17-22 12:00PM
Mar-14-22 04:00PM
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Broadfoot Jill MarieChief Financial OfficerFeb 06Sale1.691,5902,68720,821Feb 06 08:18 PM
Shukla SanjayPresident and CEODec 12Buy1.1812,00014,136106,173Dec 12 06:50 PM
Shukla SanjayPresident and CEODec 11Buy1.173,0003,51094,173Dec 12 06:50 PM
Shukla SanjayPresident and CEONov 13Buy1.1113,57815,08591,173Nov 13 04:11 PM
Shukla SanjayPresident and CEONov 10Buy1.141,4221,61877,595Nov 13 04:11 PM
Shukla SanjayPresident and CEOJul 28Buy2.0115,00030,22476,173Aug 01 04:07 PM
SCHIMMEL PAULDirectorMay 10Buy2.25200,000450,000313,023May 11 09:00 AM